Clinical trials
Non-small Cell Lung Cancer Stage III clinical trials
Below are recruiting non-small cell lung cancer stage iii clinical trials, each written for real people, not researchers. We’re tracking 233 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06262321RecruitingPhase 2
Chest Radiation for Advanced Lung Cancer at High Risk of Symptoms
This study tests whether giving radiation to tumors in the chest soon after starting systemic therapy can help prevent symptoms like pain, trouble breathing, or bleeding. It is for people with advanced non-small cell lung cancer that does not have certain gene changes and has high-risk tumors in the chest.
Rochester, New YorkAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT06272864Recruiting
A study looking at genetics of certain advanced cancers
This study tests the genes of your cancer to learn more about advanced breast, lung, melanoma, or sarcoma tumors. It may help doctors find better ways to treat these cancers in the future.
Rogers, ArkansasAges 18 years+ - NCT06275360RecruitingPhase 2
Immunotherapy re-treatment for veterans with lung cancer
This trial tests whether restarting immunotherapy along with chemotherapy and radiation can help veterans with stage III lung cancer that cannot be removed by surgery. It's for people whose tumors have a certain protein (PD-L1) and who haven't had these treatments before for advanced cancer.
West Haven, ConnecticutAges 18 years+ - NCT06284317RecruitingPhase 3
Durvalumab after chemo and surgery for early lung cancer
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
Camperdown, New South WalesAges 18 years+ - NCT06300177RecruitingPhase 3
New targeted pill vs. chemotherapy for KRAS G12C lung cancer
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
Hefei, AnhuiAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without another drug for advanced EGFR-mutant lung cancer
This trial tests whether adding a new drug (datopotamab deruxtecan) to the standard targeted therapy osimertinib works better for advanced non-small cell lung cancer with certain EGFR mutations. It is for people who have not had chemotherapy or targeted therapy before.
Fountain Valley, CaliforniaAges 18 years+ - NCT06369181Recruiting
Study on cell changes in lung cancer with RB1/TP53 gene changes
This trial looks at what happens when certain types of non-small cell lung cancer—those with changes in the RB1 and TP53 genes—start to change into another type of lung cancer after treatment. It may help find better ways to treat this specific kind of cancer in the future.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06379087RecruitingPhase 2
Radiation, immunotherapy and targeted therapy for early-stage lung cancer
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
Hangzhou, ZhejiangAges 18–75 - NCT06388031RecruitingPhase 2
Re-trying immunotherapy for advanced lung cancer after long-term success
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
BeijingAges 18–80 - NCT06403111RecruitingPhase 2
FMT with immunotherapy and chemotherapy for advanced lung cancer
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
ChangzhouAges 18–80 - NCT06424067RecruitingPhase 2
Fingolimod for advanced lung cancer
This trial tests if the drug fingolimod can help people with advanced non-small cell or small cell lung cancer that has worsened after at least two previous treatments. Fingolimod is a pill taken daily that may help the immune system fight the cancer.
Charleston, South CarolinaAges 18 years+ - NCT06424899RecruitingPhase 2
Chemoimmunotherapy before and after chemoradiation for stage III lung cancer
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT06428422Recruiting
Probiotic supplement for advanced lung cancer
This trial tests if taking a probiotic supplement along with your standard lung cancer treatment can help you live longer and respond better to therapy. It is for people with advanced non-small cell lung cancer who have not tried immunotherapy before.
KonyaAges 19–90 - NCT06437977RecruitingPhase 3
Pre-surgery treatment with radiation, immunotherapy, and chemo for stage II-III NSCLC
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
ShanghaiAges 18–75 - NCT06448572RecruitingPhase 1/Phase 2
EXL01 and nivolumab for immunotherapy-resistant lung cancer
This trial tests an investigational microbiome therapy (EXL01) combined with nivolumab (an immunotherapy) for people with advanced non-small cell lung cancer whose cancer continued to grow after standard immunotherapy and chemotherapy. The goal is to see if adding EXL01 can help the immune system fight the cancer again.
LilleAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06467383Recruiting
Study of lung cancer care after surgery or radiation
This study is looking back at the medical records of people with early-stage non-small cell lung cancer who had surgery or radiation therapy between 2018 and 2019. The goal is to understand how patients were diagnosed and treated, which may help improve care for others in the future.
San Giovanni Rotondo, FGAges 18 years+ - NCT06495125RecruitingPhase 2
Study of three drugs for a type of advanced lung cancer
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Atlanta, GeorgiaAges 18 years+ - NCT06534489Recruiting
Surgery for lung cancer after chemo or targeted therapy
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
ShanghaiAges 18–75
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell lung cancer stage iii?
- Yes. Clin2 currently lists 233 recruiting non-small cell lung cancer stage iii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell lung cancer stage iii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell lung cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Unresectable Stage III Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.